Skip to main content
Figure 3 | Cardiovascular Diabetology

Figure 3

From: Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study

Figure 3

Postprandial percent decrease in FMD [(postprandial FMD-fasting FMD) × 100/fasting FMD] in the control, acarbose and nateglinide groups after 12 weeks of treatment. The postprandial decrease in FMD was significantly suppressed in the acarbose group, compared to the control and nateglinide groups. The postprandial FMD decrease in nateglinide group was also suppressed compared to the control group.

Back to article page